NR AHAK
AU Laperche,S.
TI [Creutzfeldt-Jakob disease and transfusional risk: the point in 1998]
OT Maladie de Creutzfeldt-Jakob et risque transfusionnel: le point en 1998.
QU Transfusion Clinique et Biologique 1999 Feb; 6(1): 67-71
PT journal article; review; review, tutorial
AB As both iatrogenic and experimental transmission of Creutzfeldt-Jakob disease (CJD) have been demonstrated, potential blood transfusion-related CJD through blood component contamination is not unlikely. Recent studies also suggest that B lymphocytes would play a crucial role in the disease pathogenesis. However, to date, there is no epidemiological evidence suggesting that classical transmission of CJD would involve B lymphocytes. To reduce the theoretical risk of such transmission and as no biological marker of the disease is currently available, at-risk blood donors are excluded and leukocyte depletion has been introduced. Furthermore, the recent discovery of a new variant of the disease (nwCJD) which is caused by the bovine agent and has typical tropism for lymphoreticular tissues should lead to close surveillance.
IN Der Autor behauptet, dass wegen des theoretischen Risikos einer CJD-Übertragung durch Blut besonderen Risiken unterworfene Personengruppen von Blutspenden ausgeschlossen seien und wegen der experimentell beobachteten Rolle der B-Lymphozyten Leukozytenabreicherungen durchgeführt würden. Wegen der Entdeckung der neuen CJD-Variante, deren BSE-Herkunft er als bewiesen darstellt, hält er eine strikte Überwachung der Creutzfeldt-Jakob-Krankheit für erforderlich.
ZR 10
MH Animal; B-Lymphocytes/immunology; Blood Transfusion/*adverse effects; Cattle; Creutzfeldt-Jakob Syndrome/epidemiology/*transmission; English Abstract; France/epidemiology; Human; Risk Factors
AD Laboratoire de virologie transfusionnelle, Institut national de la transfusion sanguine, Paris.
SP französisch
PO Frankreich